446 related articles for article (PubMed ID: 21844037)
21. European perspectives on pediatric formulations.
Breitkreutz J
Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
[TBL] [Abstract][Full Text] [Related]
22. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
23. For the European Medicines Agency, a decade of challenges.
Rice M
J Natl Cancer Inst; 2005 Oct; 97(19):1403-5. PubMed ID: 16204689
[No Abstract] [Full Text] [Related]
24. Regulatory structures for gene therapy medicinal products in the European Union.
Klug B; Celis P; Carr M; Reinhardt J
Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
[TBL] [Abstract][Full Text] [Related]
25. [The role of the Danish Medical Products Agency in clinical trials].
Simonsen AC
Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
[TBL] [Abstract][Full Text] [Related]
26. The European Regulation on medicines for paediatric use.
Dunne J
Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
[TBL] [Abstract][Full Text] [Related]
27. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
28. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
29. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
[TBL] [Abstract][Full Text] [Related]
30. The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
Moulon I; Dedes N
J Ambul Care Manage; 2010; 33(3):190-7. PubMed ID: 20539145
[TBL] [Abstract][Full Text] [Related]
31. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
32. Statisticians in European regulatory agencies.
Skovlund E
Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357
[TBL] [Abstract][Full Text] [Related]
33. [Dissection of differences and similarities of botanical drugs in European Union, US and Canada].
He Y; Zhao L; Ye Z; Guo Z; Sun H
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(19):2747-50. PubMed ID: 22242441
[TBL] [Abstract][Full Text] [Related]
34. European medicines agency: riddled with conflicts of interest.
Prescrire Int; 2012 Nov; 21(132):278. PubMed ID: 23210268
[No Abstract] [Full Text] [Related]
35. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
36. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
37. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
38. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
39. [National Agency for Medicaments (ANAMED, Chile): an opportunity not to be missed].
Espinoza S MA; Cabieses B
Rev Med Chil; 2011 Dec; 139(12):1624-5. PubMed ID: 22446712
[No Abstract] [Full Text] [Related]
40. New pathway for qualification of novel methodologies in the European Medicines Agency.
Manolis E; Vamvakas S; Isaac M
Proteomics Clin Appl; 2011 Jun; 5(5-6):248-55. PubMed ID: 21538915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
